Myung-Ju Ahn

Myung-Ju Ahn

UNVERIFIED PROFILE

Are you Myung-Ju Ahn?   Register this Author

Register author
Myung-Ju Ahn

Myung-Ju Ahn

Publications by authors named "Myung-Ju Ahn"

Are you Myung-Ju Ahn?   Register this Author

100Publications

2567Reads

-Profile Views

Impact of EGFR mutation on the clinical efficacy of PD-1 inhibitors in patients with pulmonary adenocarcinoma.

J Cancer Res Clin Oncol 2019 May 21;145(5):1341-1349. Epub 2019 Mar 21.

Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Republic of Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00432-019-02889-0DOI Listing
May 2019

Combination of Osimertinib with Durvalumab in Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer: Is There Room for Reinvestigation?

Authors:
Myung-Ju Ahn

J Thorac Oncol 2019 May;14(5):766-767

Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2019.03.005DOI Listing
May 2019

Histopathologic characteristics of advanced-stage ROS1-rearranged non-small cell lung cancers.

Pathol Res Pract 2019 May 6:152441. Epub 2019 May 6.

Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.prp.2019.152441DOI Listing
May 2019

Paired whole exome and transcriptome analyses for the Immunogenomic changes during concurrent chemoradiotherapy in esophageal squamous cell carcinoma.

J Immunother Cancer 2019 May 16;7(1):128. Epub 2019 May 16.

Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-Gu, Seoul, 60351, Republic of Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-019-0609-xDOI Listing
May 2019

Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib.

Cancer Res Treat 2019 Apr 13;51(2):502-509. Epub 2018 Jun 13.

Division of Hematology-Oncology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4143/crt.2018.117DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6473268PMC
April 2019

Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea.

Cancer Res Treat 2019 Apr 23;51(2):623-631. Epub 2018 Jul 23.

Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

View Article

Download full-text PDF

Source
http://www.e-crt.org/journal/view.php?doi=10.4143/crt.2018.1
Publisher Site
http://dx.doi.org/10.4143/crt.2018.151DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6473281PMC
April 2019

The First-week Proliferative Response of Peripheral Blood PD-1CD8 T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors.

Clin Cancer Res 2019 Apr 15;25(7):2144-2154. Epub 2019 Jan 15.

Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology, Daejeon, Republic of Korea.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/lookup/doi/10.1158/107
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-18-1449DOI Listing
April 2019

Repeat biopsy procedures and T790M rates after afatinib, gefitinib, or erlotinib therapy in patients with lung cancer.

Lung Cancer 2019 Apr 28;130:87-92. Epub 2019 Jan 28.

Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2019.01.012DOI Listing
April 2019

Dosimetric predictors for postoperative pulmonary complications in esophageal cancer following neoadjuvant chemoradiotherapy and surgery.

Radiother Oncol 2019 Apr 21;133:87-92. Epub 2019 Jan 21.

Department of Radiation Oncology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.radonc.2019.01.005DOI Listing
April 2019

Advanced Stage Non-Small Cell Lung Cancer: Advances in Thoracic Oncology 2018.

J Thorac Oncol 2019 Apr 16. Epub 2019 Apr 16.

Guangdong Lung Cancer Institute; Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences; Guangzhou; China.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15560864193028
Publisher Site
http://dx.doi.org/10.1016/j.jtho.2019.03.022DOI Listing
April 2019

Incidence of brain metastasis in lung adenocarcinoma at initial diagnosis on the basis of stage and genetic alterations.

Lung Cancer 2019 Mar 28;129:28-34. Epub 2018 Dec 28.

Division of Pulmonology and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2018.12.027DOI Listing
March 2019

Correlations between metabolic texture features, genetic heterogeneity, and mutation burden in patients with lung cancer.

Eur J Nucl Med Mol Imaging 2019 02 25;46(2):446-454. Epub 2018 Aug 25.

Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, Republic of Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-018-4138-5DOI Listing
February 2019

Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC.

J Thorac Oncol 2019 Feb 1;14(2):193-202. Epub 2018 Nov 1.

Division of Hematology-Oncology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15560864183338
Publisher Site
http://dx.doi.org/10.1016/j.jtho.2018.10.150DOI Listing
February 2019

Correction to: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018).

Authors:
Sneha Berry Nicolas Giraldo Peter Nguyen Benjamin Green Haiying Xu Aleksandra Ogurtsova Abha Soni Farah Succaria Daphne Wang Charles Roberts Julie Stein Elizabeth Engle Drew Pardoll Robert Anders Tricia Cottrell Janis M Taube Ben Tran Mark Voskoboynik James Kuo Yung-Lue Bang Hyun-Cheo Chung Myung-Ju Ahn Sang-We Kim Ayesh Perera Daniel Freeman Ikbel Achour Raffaella Faggioni Feng Xiao Charles Ferte Charlotte Lemech Funda Meric-Bernstam Theresa Werner Stephen Hodi Wells Messersmith Nancy Lewis Craig Talluto Mirek Dostalek Aiyang Tao Sarah McWhirter Damian Trujillo Jason Luke Chunxiao Xu BoMarelli Jin Qi Guozhong Qin Huakui Yu Molly Jenkins Kin-Ming Lo Joern-Peter Halle Yan Lan Matthew Taylor Nicholas Vogelzang Allen Cohn Daniel Stepan Robert Shumaker Corina Dutcus Matthew Guo Emmett Schmidt Drew Rasco Marcia Brose Nicholas Vogelzang Christopher Di Simone Sharad Jain Donald Richards Carlos Encarnacion Drew Rasco Robert Shumaker Corina Dutcus Daniel Stepan Matthew Guo Emmett Schmidt Matthew Taylor Nicholas Vogelzang Carlos Encarnacion Allen Cohn Christopher Di Simone Drew Rasco Donald Richards Matthew Taylor Corina Dutcus Daniel Stepan Robert Shumaker Matthew Guo Emmett Schmidt James Mier Jeongshin An Yeun-Yeoul Yang Won-Hee Lee Jinho Yang Jong-Kyu Kim Hyun Goo Kim Se Hyun Paek Jun Woo Lee Joohyun Woo Jong Bin Kim Hyungju Kwon Woosung Lim Nam Sun Paik Yoon-Keun Kim Byung-In Moon Filip Janku David Tan Juan Martin-Liberal Shunji Takahashi Ravit Geva Ayca Gucalp Xueying Chen Kulandayan Subramanian Jennifer Mataraza Jennifer Wheler Philippe Bedard

J Immunother Cancer 2019 Feb 13;7(1):46. Epub 2019 Feb 13.

Princess Margaret Cancer Centre, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-019-0519-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6373015PMC
February 2019

Improved treatment outcome of pembrolizumab in patients with nonsmall cell lung cancer and chronic obstructive pulmonary disease.

Int J Cancer 2019 Feb 26. Epub 2019 Feb 26.

Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.32235DOI Listing
February 2019

Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-mutated Non-small Cell Lung Cancer.

Cancer Res Treat 2019 Jan 23;51(1):408-412. Epub 2018 May 23.

Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4143/crt.2018.138DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6333983PMC
January 2019

Current status of immune checkpoint inhibitors in treatment of non-small cell lung cancer.

Korean J Intern Med 2019 Jan 3;34(1):50-59. Epub 2018 Sep 3.

Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3904/kjim.2018.179DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6325449PMC
January 2019

Clinical outcomes of radiation therapy for clinical T4b oesophageal cancer with airway invasion.

Radiat Oncol 2018 Dec 14;13(1):245. Epub 2018 Dec 14.

Department of Thoracic Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13014-018-1196-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6295084PMC
December 2018

Efficacy and Safety of Lorlatinib in Korean Non-Small-Cell Lung Cancer Patients With ALK or ROS1 Rearrangement Whose Disease Failed to Respond to a Previous Tyrosine Kinase Inhibitor.

Clin Lung Cancer 2018 Dec 31. Epub 2018 Dec 31.

Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15257304183035
Publisher Site
http://dx.doi.org/10.1016/j.cllc.2018.12.020DOI Listing
December 2018

Transthoracic Rebiopsy for Mutation Analysis in Lung Adenocarcinoma: Outcomes and Risk Factors for the Acquisition of Nondiagnostic Specimens in 199 Patients.

Clin Lung Cancer 2018 Dec 31. Epub 2018 Dec 31.

Department of Radiology, Samsung Medical Center, Seoul, Korea; Sungkyunkwan University School of Medicine, Seoul, Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2018.12.021DOI Listing
December 2018

Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer.

J Clin Oncol 2018 Nov 29;36(31):3101-3109. Epub 2018 Aug 29.

Yi-Long Wu, Guangdong General Hospital and Guangdong Academy of Medical Sciences; Li Zhang, Sun Yat-sen University Cancer Center, Guangdong; Xiaoqing Liu, Affiliated Hospital of the Chinese Academy of Military Medical Sciences, Beijing; Sylvia Zhao and Bin Peng, Novartis Institutes for Biomedical Research, Shanghai, People's Republic of China; Dong-Wan Kim, Seoul National University Hospital; Dae Ho Lee, University of Ulsan College of Medicine; Myung-Ju Ahn, Samsung Medical Center, Seoul, Republic of Korea; James Chih-Hsin Yang, National Taiwan University Hospital, Taipei; Wu-Chou Su, National Cheng Kung University Hospital, Tainan, Taiwan; Johan F. Vansteenkiste, University Hospital KU Leuven, Leuven, Belgium; Enriqueta Felip, Vall d'Hebron University Hospital, Barcelona, Spain; Vincent Chia and Philippe Pultar, Novartis Pharmaceuticals, East Hanover, NJ; Sabine Glaser and Mikhail Akimov, Novartis Pharma AG, Basel, Switzerland; and Daniel S.W. Tan, National Cancer Centre Singapore, Singapore.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.77.7326DOI Listing
November 2018

Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer.

N Engl J Med 2018 11 25;379(21):2027-2039. Epub 2018 Sep 25.

From the University of Colorado Cancer Center, Aurora (D.R.C.); Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine (H.R.K.), Samsung Medical Center (M.-J.A.), and Seoul National University Hospital (D.-W.K.), Seoul, National Cancer Center, Goyang (J.-Y.H.), Seoul National University Bundang Hospital, Seongnam (J.-S.L.), and Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju (K.H.L.) - all in South Korea; National Taiwan University Hospital (J.C.-H.Y.) and the Faculty of Medicine, School of Medicine, National Yang-Ming University (G.-C.C.), Taipei, and the Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung (G.-C.C.) - all in Taiwan; the Ludwig Boltzmann Institute for COPD and Respiratory Epidemiology, Department of Respiratory and Critical Care Medicine, Otto Wagner Hospital, Vienna (M.J.H.); Queen Elizabeth Hospital, Kowloon, Hong Kong (J.Y.-C.L.); Azienda Ospedaliera S. Giuseppe Moscati, Avellino (C.G.), the Scientific Institute of Romagna for the Study and Treatment of Cancer, Meldola (A.D.), Centro di Riferimento Oncologico, Istituto Nazionale Tumori, IRCCS Struttura Operativa Complessa Oncologia Medica A, Aviano (A.B.), Thoracic Medical Oncology, Istituto Nazionale Tumori, IRCCS Fondazione G. Pascale, Naples (A.M.), and the Medical Oncology Unit, University Hospital of Parma, Parma (M.T.) - all in Italy; Complejo Hospitalario Universitario de A Coruña, Coruña (R.G.C.), and Vall d'Hebron University Hospital, Barcelona (E.F.) - both in Spain; the Department of Hematology and Oncology, University Department of Internal Medicine-Oncology, Pius-Hospital Medical Campus, University of Oldenburg, Oldenburg, Germany (F.G.); the Department of Medical Oncology, Christie NHS Foundation Trust, and Division of Cancer Sciences, University of Manchester, Manchester (R.C.), and Guy's and St. Thomas' NHS Foundation Trust (S.G.) and Royal Marsden Hospital and the National Heart and Lung Institute, Imperial College London (S.P.), London - all in the United Kingdom; Virginia Cancer Specialists Research Institute and US Oncology Research, The Woodlands, TX (A.S.); Yale Cancer Center, New Haven, CT (S.N.G.); and Millennium Pharmaceuticals, Cambridge, MA (N.G., J.H., D.K.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1810171DOI Listing
November 2018

Continuation of gefitinib beyond progression in patients with EGFR mutation-positive non-small-cell lung cancer: A phase II single-arm trial.

Lung Cancer 2018 10 3;124:293-297. Epub 2018 Aug 3.

Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01695002183051
Publisher Site
http://dx.doi.org/10.1016/j.lungcan.2018.08.003DOI Listing
October 2018

Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials.

J Clin Oncol 2018 Sep 16;36(26):2693-2701. Epub 2018 May 16.

D. Ross Camidge, University of Colorado Cancer Center, Aurora, CO; Dong-Wan Kim, Seoul National University Hospital; Myung-Ju Ahn, Samsung Medical Center; Dae Ho Lee, Asan Medical Center, Seoul, South Korea; Marcello Tiseo, University Hospital of Parma, Parma, Italy; Corey J. Langer, University of Pennsylvania, Philadelphia, PA; Alice T. Shaw, Massachusetts General Hospital, Boston; William Reichmann, Jeff Haney, Tim Clackson, and David Kerstein, ARIAD Pharmaceuticals, Cambridge, MA; Rudolf M. Huber, University Hospital of Munich, Munich, Germany; Maximilian J. Hochmair, Otto Wagner Hospital, Vienna, Austria; Lyudmila A. Bazhenova and Kathryn A. Gold, University of California San Diego Moores Cancer Center, La Jolla; Sai-Hong Ignatius Ou, University of California Irvine School of Medicine, Irvine, CA; Howard L. West, Swedish Cancer Institute, Seattle, WA; and Scott N. Gettinger, Yale Cancer Center, New Haven, CT.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.77.5841
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.77.5841DOI Listing
September 2018

Characteristics and Outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice.

J Thorac Oncol 2018 09 5;13(9):1373-1382. Epub 2018 Jun 5.

Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.05.026DOI Listing
September 2018

CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3).

J Clin Oncol 2018 Sep 30;36(26):2702-2709. Epub 2018 Jul 30.

Yi-Long Wu, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Myung-Ju Ahn, Sungkyunkwan University School of Medicine; Hye Ryun Kim, Yonsei University College of Medicine, Seoul; Ji-Youn Han, National Cancer Center, Goyang, Republic of Korea; Marina Chiara Garassino, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Nobuyuki Katakami, Institute of Biomedical Research and Innovation, Kobe, Japan; Rachel Hodge, Paramjit Kaur, Andrew P. Brown, and Dana Ghiorghiu, AstraZeneca, Cambridge, United Kingdom; Vassiliki A. Papadimitrakopoulou, The University of Texas MD Anderson Cancer Center, Houston, TX; and Tony S.K. Mok, Chinese University of Hong Kong, Hong Kong.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.77.9363DOI Listing
September 2018

Transient Asymptomatic Pulmonary Opacities During Osimertinib Treatment and its Clinical Implication.

J Thorac Oncol 2018 08;13(8):1106-1112

Division of Hematology-Oncology, Departments of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2018.04.038DOI Listing
August 2018

Acquired resistance to AZD9291 as an upfront treatment is dependent on ERK signaling in a preclinical model.

PLoS One 2018 11;13(4):e0194730. Epub 2018 Apr 11.

Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0194730PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5895014PMC
July 2018

Phase I Trial of Anti-MET Monoclonal Antibody in MET-Overexpressed Refractory Cancer.

Clin Colorectal Cancer 2018 06 31;17(2):140-146. Epub 2018 Jan 31.

Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clcc.2018.01.005DOI Listing
June 2018

Deciphering Clinicoradiologic Phenotype for Thymidylate Synthase Expression Status in Patients with Advanced Lung Adenocarcinoma Using a Radiomics Approach.

Sci Rep 2018 Jun 12;8(1):8968. Epub 2018 Jun 12.

Division of Hematology-Oncology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-018-27273-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5997691PMC
June 2018

Pembrolizumab for Patients With Refractory or Relapsed Thymic Epithelial Tumor: An Open-Label Phase II Trial.

J Clin Oncol 2018 Jun 15:JCO2017773184. Epub 2018 Jun 15.

Jinhyun Cho, Inha University Hospital, Inha University School of Medicine, Incheon; Hae Su Kim, Veterans Health Service Medical Center; Bo Mi Ku, Yoon-La Choi, Joungho Han, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, and Myung-Ju Ahn, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea; Korea; and Razvan Cristescu, Merck Research Laboratories, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.77.3184DOI Listing
June 2018

Efficacy and safety of cisplatin and weekly docetaxel in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

Korean J Intern Med 2018 Jun 20. Epub 2018 Jun 20.

Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3904/kjim.2017.234DOI Listing
June 2018

Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer.

J Clin Oncol 2018 May 29;36(14):1405-1411. Epub 2018 Mar 29.

Yi-Long Wu and Jin-Ji Yang, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou; Shun Lu, Jiao Tong University, Shanghai; Jianying Zhou, First Affiliated Hospital of Zhejiang University, Hangzhou, People's Republic of China; James Chih-Hsin Yang, National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, Republic of China; Dong-Wan Kim, Seoul National University Hospital; Myung-Ju Ahn, Samsung Medical Center, Seoul, South Korea; Takashi Seto, National Kyushu Cancer Center, Fukuoka; Noboru Yamamoto, National Cancer Center Hospital, Tokyo; Toshiaki Takahashi, Shizuoka Cancer Center, Shizuoka; Takeharu Yamanaka, Yokohama City University School of Medicine, Yokohama; Koichi Goto, National Cancer Center Hospital East, Kashiwa, Japan; Allison Kemner and Debasish Roychowdhury, OxOnc Development, Princeton, NJ; Nirvan Consultants, Lexington, MA; Jolanda Paolini and Tiziana Usari, Pfizer, Milan, Italy; and Keith D. Wilner, Pfizer, La Jolla, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.75.5587DOI Listing
May 2018

Association of Cancer Cell Type and Extracellular Vesicles With Coagulopathy in Patients With Lung Cancer and Stroke.

Stroke 2018 05 2;49(5):1282-1285. Epub 2018 Apr 2.

From the Departments of Neurology (J.-W.C., M.J.L., G.-M.K., C.-S.C., O.Y.B.)

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1161/STROKEAHA.118.020995DOI Listing
May 2018

Afatinib in heavily pretreated advanced NSCLC patients who progressed following prior gefitinib or erlotinib: Compassionate use program in Korea.

Lung Cancer 2018 05 6;119:36-41. Epub 2018 Mar 6.

Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2018.02.020DOI Listing
May 2018

Blood Droplet-Based Cancer Diagnosis via Proteolytic Activity Measurement in Cancer Progression.

Theranostics 2017 8;7(11):2878-2887. Epub 2017 Jul 8.

SKKU Advanced Institute of Nano Technology (SAINT), Sungkyunkwan University (SKKU), Suwon 16419, Republic of Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7150/thno.19358DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5562222PMC
April 2018

KIF5B-MET Gene Rearrangement with Robust Antitumor Activity in Response to Crizotinib in Lung Adenocarcinoma.

J Thorac Oncol 2018 03 2;13(3):e29-e31. Epub 2017 Nov 2.

Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2017.10.014DOI Listing
March 2018

Pazopanib maintenance after first-line etoposide and platinum chemotherapy in patients with extensive disease small-cell lung cancer: a multicentre, randomised, placebo-controlled Phase II study (KCSG-LU12-07).

Br J Cancer 2018 03 30;118(5):648-653. Epub 2018 Jan 30.

Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/bjc.2017.465DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5846070PMC
March 2018

Late-Onset Cholecystitis with Cholangitis after Avelumab Treatment in Non-Small Cell Lung Cancer.

J Thorac Oncol 2018 03;13(3):e34-e36

Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2017.10.007DOI Listing
March 2018

Temporal and regional distribution of initial recurrence site in completely resected N1-stage II lung adenocarcinoma: The effect of postoperative adjuvant chemotherapy.

Lung Cancer 2018 03 6;117:7-13. Epub 2018 Jan 6.

Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2018.01.004DOI Listing
March 2018

Consolidation of immunotherapy becomes new standard of care in unresectable stage III non-small cell lung cancer.

Authors:
Myung-Ju Ahn

J Thorac Dis 2018 Mar;10(3):1205-1206

Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd.2018.03.55DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5906269PMC
March 2018

Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer.

J Thorac Oncol 2018 01 31;13(1):106-111. Epub 2017 Oct 31.

Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2017.10.011DOI Listing
January 2018

Cell-free DNA Analysis in SCLC: Ready for Clinical Practice?

Authors:
Myung-Ju Ahn

J Thorac Oncol 2018 01;13(1):10-11

Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2017.10.003DOI Listing
January 2018

Recurrence dynamics after trimodality therapy (Neoadjuvant concurrent chemoradiotherapy and surgery) in patients with stage IIIA (N2) lung cancer.

Lung Cancer 2018 01 22;115:89-96. Epub 2017 Nov 22.

Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2017.11.020DOI Listing
January 2018

Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors.

Invest New Drugs 2017 Dec 8;35(6):782-790. Epub 2017 Apr 8.

Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro Gangnam-gu, Seoul, 06351, South Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-017-0463-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5694508PMC
December 2017

Randomized Phase II Trial Comparing Chemoradiotherapy with Chemotherapy for Completely Resected Unsuspected N2-Positive Non-Small Cell Lung Cancer.

J Thorac Oncol 2017 12 28;12(12):1806-1813. Epub 2017 Sep 28.

Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2017.09.1954DOI Listing
December 2017

Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses.

J Clin Oncol 2017 Dec 2;35(36):4027-4034. Epub 2017 Oct 2.

Tony S.K. Mok, The Chinese University of Hong Kong, Prince of Wales Hospital, Sha Tin, Hong Kong, Special Administrative Region, People's Republic of China; Yi-Long Wu and Jin-Ji Yang, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou; Jie Wang, Peking University School of Oncology, Beijing Cancer Hospital and Institute, Beijing; You Lu, Sichuan University, Sichuan; Xiaojin Shi, AstraZeneca, Shanghai, People's Republic of China; James Chih-Hsin Yang, The National Taiwan University Hospital and College of Medicine, Taipei, Taiwan, Republic of China; Sang-We Kim, University of Ulsan College of Medicine; Myung-Ju Ahn, Sungkyunkwan University School of Medicine, Seoul, South Korea; Kazuhiko Nakagawa, Kindai University; Shinji Atagi, Kinkichuo Chest Medical Center, Osaka, Japan; Santiago Ponce, Hospital Universitario 12 de Octubre, Madrid, Spain; Yuri Rukazenkov, AstraZeneca, Cambridge; Vincent Haddad, AstraZeneca, Royston, United Kingdom; Kenneth S. Thress, AstraZeneca, Waltham, MA; and Jean-Charles Soria, Gustave Roussy Cancer Campus and University Paris-Sud, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.73.9250DOI Listing
December 2017

Genetic Alterations and Their Clinical Implications in High-Recurrence Risk Papillary Thyroid Cancer.

Cancer Res Treat 2017 Oct 26;49(4):906-914. Epub 2016 Dec 26.

Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4143/crt.2016.424DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5654158PMC
October 2017

Characteristics and outcomes of ALK+ non-small cell lung cancer patients in Korea.

Asia Pac J Clin Oncol 2017 Oct 16;13(5):e239-e245. Epub 2017 Apr 16.

Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ajco.12645DOI Listing
October 2017

An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer.

Expert Rev Mol Diagn 2017 10 30;17(10):933-942. Epub 2017 Aug 30.

b Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center , Sungkyunkwan University School of Medicine , Seoul , Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737159.2017.1372196DOI Listing
October 2017

Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer.

J Clin Oncol 2017 Oct 30;35(30):3449-3457. Epub 2017 Aug 30.

Ramaswamy Govindan, Washington University School of Medicine, St Louis, MO; Aleksandra Szczesna, Mazowieckie Centrum Leczenia Chorób Płuc i Gruźlicy, Otwock; Jacek Jassem, Medical University of Gdansk, Gdansk, Poland; Myung-Ju Ahn, Samsung Medical Center, Sungkyunkwan University, Seoul; Ki Hyeong Lee, Chungbuk National University Hospital, Cheongju-si, Republic of Korea; Claus-Peter Schneider, Zentralklinik Bad Berka, Bad Berka; Joachim Von Pawel, Asklepius Fachkliniken, Gauting; Martin Reck, LungenClinic Grosshansdorf, Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany; Pablo Fernando Gonzalez Mella, Centro de Investigaciones Clinicas, Universidad de Valparaíso and Fundación Arturo López Pérez, Santiago, Chile; Fabrice Barlesi, Aix Marseille University, Assistance Publique-Hôpitaux de Marseille, Marseille, France; Baohui Han, Shanghai Chest Hospital Affiliated to Shanghai JiaoTong University, Shanghai; Li Zhang, Sun Yat-Sen University Cancer Center, Guangzhou, People's Republic of China; Doina Elena Ganea, Spitalul Judetean De Urgenta Suceava, Sfântul loan cel Nou, Suceava, Romania; Vladimir Vladimirov, State Healthcare Institute, Pyatigorsk Oncology Dispensary, Pyatigorsk; Natalia Fadeeva, Chelyabinsk Regional Oncology Dispensary, Chelyabinsk, Russian Federation; Takayasu Kurata, Kansai Medical University Hirakata Hospital, Osaka; Tomohide Tamura, St Luke's International Hospital, Tokyo, Japan; Pieter E. Postmus, University of Liverpool, Liverpool, United Kingdom; Kenneth O'Byrne, Princess Alexandra Hospital and Queensland University of Technology, Brisbane, Queensland, Australia; and Justin Kopit, Mingshun Li, and Marina Tschaika, Bristol-Myers Squibb, Princeton, NJ.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2016.71.7629
Publisher Site
http://dx.doi.org/10.1200/JCO.2016.71.7629DOI Listing
October 2017

Phase 2 study of intermittent pulse dacomitinib in patients with advanced non-small cell lung cancers.

Lung Cancer 2017 10 23;112:195-199. Epub 2017 Aug 23.

Lombardi Comprehensive Cancer Center, Georgetown University, 3970 Reservoir Road Washington DC 20007, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2017.08.017DOI Listing
October 2017

Comparison of RECIST to immune-related response criteria in patients with non-small cell lung cancer treated with immune-checkpoint inhibitors.

Cancer Chemother Pharmacol 2017 Sep 21;80(3):591-598. Epub 2017 Jul 21.

Division of Hematology-Oncology, Departments of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-017-3396-4DOI Listing
September 2017

Mutational status of defines the efficacy of Wee1 inhibitor AZD1775 in -mutant non-small cell lung cancer.

Oncotarget 2017 Sep 28;8(40):67526-67537. Epub 2017 Jun 28.

Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.18728DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5620191PMC
September 2017

Antineutrophil Cytoplasmic Antibody-Associated Rapid Progressive Glomerulonephritis after Pembrolizumab Treatment in Thymic Epithelial Tumor: A Case Report.

J Thorac Oncol 2017 08 22;12(8):e103-e105. Epub 2017 Mar 22.

Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2017.03.011DOI Listing
August 2017

Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial.

J Clin Oncol 2017 Aug 5;35(22):2490-2498. Epub 2017 May 5.

Dong-Wan Kim, Seoul National University Hospital; Myung-Ju Ahn, Samsung Medical Center; Sang-We Kim, Asan Medical Center, Seoul, South Korea; Marcello Tiseo, University Hospital of Parma, Parma, Italy; Karen L. Reckamp, City of Hope, Duarte, CA; Karin Holmskov Hansen, Odense University Hospital, Odense, Denmark; Rudolf M. Huber, University Hospital of Munich, German Centre for Lung Research, Munich, Germany; Howard L. West, Swedish Cancer Institute, Seattle, WA; Harry J.M. Groen, University of Groningen, University Medical Center Groningen, Groningen; Egbert F. Smit, VU University Medical Center, Amsterdam, the Netherlands; Maximilian J. Hochmair, Otto Wagner Hospital, Vienna, Austria; Natasha B. Leighl, Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Scott N. Gettinger, Yale Cancer Center, New Haven, CT; Corey J. Langer, University of Pennsylvania Abramson Cancer Center, Philadelphia, PA; Luis G. Paz-Ares Rodríguez, Hospital Universitario 12 de Octubre, Madrid, Spain; Edward S. Kim, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC; William Reichmann, Frank G. Haluska, and David Kerstein, ARIAD Pharmaceuticals, Cambridge, MA; and D. Ross Camidge, University of Colorado Cancer Center, Aurora, CO.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.71.5904DOI Listing
August 2017

Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement.

J Clin Oncol 2017 Aug 18;35(23):2613-2618. Epub 2017 May 18.

Sun Min Lim, Hye Ryun Kim, Hyo Sup Shim, Joo-Hang Kim, and Byoung Chul Cho, Yonsei University College of Medicine; Yun-Gyoo Lee, Yoon La Choi, and Myung-Ju Ahn, Sungkyunkwan University School of Medicine; Bong-Seog Kim, VHS Medical Center; Min Jeong Lee and Maria Kim, Yonsei University Health System, Seoul; Jong-Seok Lee and Jin-Haeng Chung, Seoul National University Bundang Hospital, Bundang; Ki Hyeong Lee, Chungbuk National University, Cheongju; Young Joo Min, University of Ulsan College of Medicine, Ulsan; Eun Kyung Cho, Gachon Medical School, Inchon; Sung Sook Lee, Inje University College of Medicine; Moon Young Choi, Inje University, Busan; Jin-Haeng Chung, Seoul National University College of Medicine, Seongnam, Republic of Korea; and Siraj M. Ali, Foundation Medicine, Cambridge, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.71.3701DOI Listing
August 2017

A Randomized Phase II Study of Leucovorin/5-Fluorouracil with or without Oxaliplatin (LV5FU2 vs. FOLFOX) for Curatively-Resected, Node-Positive Esophageal Squamous Cell Carcinoma.

Cancer Res Treat 2017 Jul 9;49(3):816-823. Epub 2016 Nov 9.

Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4143/crt.2016.417DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5512359PMC
July 2017

Outcomes of Curative-Intent Surgery and Adjuvant Treatment for Pulmonary Large Cell Neuroendocrine Carcinoma.

World J Surg 2017 07;41(7):1820-1827

Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00268-017-3908-8DOI Listing
July 2017

Metastatic Squamous Cell Carcinoma from Lung Adenocarcinoma after Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy.

J Pathol Transl Med 2017 Jul 4;51(4):441-443. Epub 2017 Apr 4.

Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4132/jptm.2016.10.18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5525031PMC
July 2017

Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.

J Clin Oncol 2017 Apr 21;35(12):1288-1296. Epub 2017 Feb 21.

James Chih-Hsin Yang and Chia-Chi Lin, National Taiwan University Hospital, Taipei; Wu-Chou Su, National Cheng Kung University Hospital, Tainan, Taiwan, Republic of China; Myung-Ju Ahn, Sungkyunkwan University; Dong-Wan Kim, Seoul National University Hospital; Sang-We Kim, Asan Medical Center, Seoul; Joo-Hang Kim, CHA University, Gyeonggi-do, Republic of Korea; Suresh S. Ramalingam, Emory University School of Medicine, Atlanta, GA; Lecia V. Sequist, Massachusetts General Hospital; Pasi A. Jänne, Dana-Farber Cancer Institute, Boston, MA; David Planchard, Institut Gustave Roussy, Villejuif, France; Enriqueta Felip, Vall d'Hebron University Hospital, Barcelona, Spain; Fiona Blackhall, The Christie Hospital; University of Manchester, Manchester; Helen Mann and Serban Ghiorghiu, AstraZeneca, Cambridge; Mireille Cantarini, AstraZeneca, Macclesfield, United Kingdom; Daniel Haggstrom, Carolinas Healthcare System, Charlotte, NC; Kiyotaka Yoh, National Cancer Center Hospital East, Kashiwa, Chiba; Tomonori Hirashima, Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Osaka, Japan; Silvia Novello, University of Turin, Turin, Italy; and Kathryn Gold, University of California San Diego Moores Cancer Center, San Diego, CA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2016.70.3223
Publisher Site
http://dx.doi.org/10.1200/JCO.2016.70.3223DOI Listing
April 2017

EGFR TKI combination with immunotherapy in non-small cell lung cancer.

Expert Opin Drug Saf 2017 Apr 8;16(4):465-469. Epub 2017 Mar 8.

a Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center , Sungkyunkwan University School of Medicine , Seoul , Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14740338.2017.1300656DOI Listing
April 2017

Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.

N Engl J Med 2017 02 6;376(7):629-640. Epub 2016 Dec 6.

From the State Key Laboratory in Oncology in South China, Sir Y.K. Pao Centre for Cancer, Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong (T.S.M.), the Division of Pulmonary Oncology, Guangdong Lung Cancer Institute, Guangdong General Hospital, and Guangdong Academy of Medical Sciences, Guangzhou (Y.-L.W.), and the Department of Respiratory Disease, Daping Hospital, Third Military Medical University, Chongqing (Y.H.) - all in China; the Department of Medicine, Division of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, (M.-J.A.), and the Yonsei Cancer Center, Department of Internal Medicine, Division of Medical Oncology, Yonsei University College of Medicine (H.R.K.), Seoul, South Korea; the Thoracic Oncology Unit, Medical Oncology Department, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milan (M.C.G.); the Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, Atlanta (S.S.R.); the Department of Medical Oncology and Haematology, Princess Margaret Cancer Centre, Toronto (F.A.S.); the Third Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan (H.A.); the Department of Thoracic Oncology, the Netherlands Cancer Institute, Plesmanlaan, Amsterdam (W.S.M.E.T.); the Clinical Research Unit, Division of Cancer Services, St. George Hospital, Kogarah, NSW, Australia (C.K.L.); the Department of Hematology-Oncology, Johann Wolfgang Goethe University Medical Center, Frankfurt am Main, Germany (M.S.); AstraZeneca, Cambridge, United Kingdom (A.T., H.M., M.M., S.G.); and the Department of Thoracic-Head and Neck Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston (V.A.P.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1612674DOI Listing
February 2017

Histologic characteristics of thymic adenocarcinomas: Clinicopathologic study of a nine-case series and a review of the literature.

Pathol Res Pract 2017 Feb 15;213(2):106-112. Epub 2016 Nov 15.

Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.prp.2016.11.012DOI Listing
February 2017

Osimertinib for the treatment of non-small cell lung cancer.

Expert Opin Pharmacother 2017 Feb;18(2):225-231

a Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center , Sungkyunkwan University School of Medicine , Seoul , Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14656566.2017.1285283DOI Listing
February 2017

Hypercoagulability and Mortality of Patients with Stroke and Active Cancer: The OASIS-CANCER Study.

J Stroke 2017 Jan 12;19(1):77-87. Epub 2016 Dec 12.

Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5853/jos.2016.00570DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5307941PMC
January 2017

Transient Asymptomatic Pulmonary Opacities during Osimertinib Treatment: "Stop or Go" Decision.

J Thorac Oncol 2016 12;11(12):2051-2052

Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2016.09.130DOI Listing
December 2016